Compliance aid labeling for medication containers

Information

  • Patent Grant
  • 8973755
  • Patent Number
    8,973,755
  • Date Filed
    Wednesday, January 25, 2012
    12 years ago
  • Date Issued
    Tuesday, March 10, 2015
    9 years ago
Abstract
The present application is directed to patient compliance aids for a medicine container. A base label may be adhered to the medication container, and one or more indicia disposed on the base label. A top label may cover at least a portion of the base label.
Description
FIELD OF THE INVENTION

The present application is directed generally to labels, and more specifically to medication container labels that function as a compliance aid for proper usage of the medicine.


BACKGROUND

More than three billion prescriptions are written each year in the United States, and an estimated $18 billion is spent on over-the-counter medications. Both prescription and over-the-counter medications are intended to be consumed by a patient according to specific instructions for dosage and frequency. Non-compliance with these instructions has been identified as a major obstacle to the effective delivery of health care. Compliance typically means consuming the correct dosage at the correct frequency as specified in the prescription or on the over-the-counter medication packaging. According to the World Health Organization, only about half of patients with chronic diseases living in developed countries comply with their medication instructions. The reasons for non-compliance are varied, ranging from simple forgetfulness, to confusion, to ambivalence. However, the effects of non-compliance are staggering, resulting in an estimated $290 billion dollars per year in avoidable medical expenses. Additionally, studies have shown that non-compliance results in about 125,000 deaths annually in the United States, and leads to 10-25 percent of hospital and nursing home admissions.


SUMMARY

The present application is directed to patient compliance aids for a medication container and methods for patient compliance with a regimen for administration of medication. An exemplary patient compliance aid may comprise a base label adhered to a medication container, and day of week indicia disposed on the base label. A time of day indicia may be associated with the day of week indicia and may also be disposed on the base label. The patient compliance aid may further comprise a top label covering at least a portion of the base label.


According to additional exemplary embodiments, the present application may be directed to methods for patient compliance with a regimen for administration of medication from a medication container. An exemplary method may comprise adhering a base label to the medication container, and displaying an indicator on the base label. The indicator may include a symbol or character representing that medication remains in the medication container. A receiving mechanism may be associated with the indicator. The receiving mechanism may be adapted to receive an entry when the medication is removed from the medication container and consumed by the patient. At least a portion of the base label may be covered with a top label.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a front view of an exemplary label according to various embodiments.



FIG. 2 is a back view of an exemplary label according to various embodiments.



FIG. 3 is a front view of an exemplary label according to various embodiments.



FIG. 4 is a back view of an exemplary label according to various embodiments.



FIG. 5A illustrates a leading edge of an exemplary label affixed to a container according to various embodiments.



FIG. 5B illustrates an exemplary label secured about a container according to various embodiments.



FIG. 6 illustrates an exemplary label secured about a container according to various embodiments.



FIG. 7 illustrates an exemplary base label secured about a container according to various embodiments.



FIG. 8 illustrates a leading edge of an exemplary top label affixed to an exemplary base label according to various embodiments.



FIG. 9 illustrates an exemplary top label affixed to an exemplary base label and partially wrapped about a container according to various embodiments.



FIG. 10 illustrates an exemplary top label with a window affixed to an exemplary base label and partially wrapped about a container according to various embodiments.



FIG. 11 illustrates an exemplary top label with a window secured about a container and a portion of a base label visible through the window according to various embodiments.



FIG. 12A is a front view of a top label according to various embodiments.



FIG. 12B is a front view of a base label according to various embodiments.



FIG. 13 is a front view of a base label according to various embodiments.



FIG. 14 is a front view of a base label according to various embodiments.



FIG. 15A illustrates an exemplary base label secured about a container according to various embodiments.



FIG. 15B illustrates an exemplary base label and top label secured about a container according to various embodiments.



FIG. 15C illustrates an exemplary base label and top label secured about a container according to various embodiments.



FIG. 16 illustrates a markable base label secured about a container according to various embodiments.



FIG. 17 illustrates a scratchable base label secured about a container according to various embodiments.



FIG. 18A illustrates an exemplary base label secured about a container according to various embodiments.



FIG. 18B illustrates an exemplary top label with a window affixed to an exemplary base label and secured about a container according to various embodiments.



FIG. 19A illustrates an exemplary base label and top label secured about a container according to various embodiments.



FIG. 19B illustrates an exemplary base label and top label secured about a container according to various embodiments.



FIG. 20 illustrates an exemplary base label and top label secured about a container according to various embodiments.



FIG. 21 is an exemplary flow diagram of a method for patient compliance with a regimen for administration of medication according to various embodiments.





DETAILED DESCRIPTION

The present application is directed to patient compliance aids for a medication container and methods for patient compliance with a regimen for administration of medication. An exemplary patient compliance aid may comprise a base label adhered to a medication container, and day of week indicia disposed on the base label. A time of day indicia may be associated with the day of week indicia and may also be disposed on the base label. The patient compliance aid may further comprise a top label covering at least a portion of the base label.



FIG. 1 illustrates various embodiments of a front surface 108 of a base label 100 for an object, such as a medication container, according to various embodiments. The base label 100 comprises a leading edge 102 and a trailing edge 104. While the leading edge 102 is oriented to the left and the trailing edge 104 is oriented to the right as presented in FIG. 1, the orientation of the leading edge 102 and the trailing edge 104 could be reversed depending on which edge is first applied to the object. Both orientations are within the scope of the present disclosure. Base label front surface 108 may comprise writing or other indicia 106 thereon.


As used herein, the leading edge refers to the first edge to be affixed to the object and the trailing edge refers to the second edge to be affixed to the object or the overlapping leading edge. Depending on the orientation of the label and the object when the label is affixed to the object, either edge of the label may be the leading edge. The orientations presented in the figures are for convenience and are not intended to be limiting in any way.



FIG. 2 illustrates various embodiments of a back surface 206 of the base label 100. In various embodiments, the base label back surface 206 comprises two strips of adhesive 202 and 204 on or immediately adjacent to the leading and trailing edges, 102 and 104, respectively. Base label leading edge adhesive 202 may have a boundary 208 defined as its limit on the base label back surface 206. Base label trailing edge adhesive 204 may also have a boundary 210. While FIG. 2 illustrates that the adhesive strips 202 and 204 are generally close to the base label leading and trailing edges 102 and 104, respectively, it is understood that the adhesive strips 202 and 204 may be continuous or discontinuous, and may extend across any portion of the base label back surface 206, including the entire base label back surface 206. In various embodiments, a length of the base label 100 may be selected to be slightly longer than a circumference of the object on which it is placed, such that the trailing edge 104 overlaps the leading edge 102, and the trailing edge 104 is affixed to the leading edge 102. In various embodiments, the length of the base label 100 may be selected to be approximately the same as the circumference of the object on which it is placed, such that the leading edge 102 and the trailing edge 104 do not overlap.



FIG. 3 illustrates various embodiments of a front surface 306 of a top label 300. Top label 300 comprises a leading edge 302 and a trailing edge 304, and indicia 308 may be imprinted on the top label front surface 306.


Various embodiments of a back surface 402 of the top label 300 are illustrated in FIG. 4. The top label back surface 402 may comprise various indicia 408 printed thereon, as well as two strips of adhesive 404 and 406 on or immediately adjacent to the leading and trailing edges, 302 and 304, respectively. Top label leading edge adhesive 404 may have a boundary 410 defined as its limit on the top label back surface 402. Top label trailing edge adhesive 406 may also have a boundary 412. While FIG. 4 illustrates that the adhesive strips 404 and 406 are generally close to the top label leading and trailing edges 302 and 304, respectively, it is understood that the adhesive strips 404 and 406 may be continuous or discontinuous, and may extend across any portion of the top label back surface 402, including the entire top label back surface 402. In various embodiments, the adhesive strips 404 and 406 are confined to areas near the leading and trailing edges 302 and 304, respectively, so as not to obscure or interfere with the top label back surface indicia 408.


The base label adhesive 202, 204 and the top label adhesive 404, 406 may be applied in a variety of patterns as can be appreciated by one skilled in the art. The adhesive 202, 204, 404, 406 may be applied in strips, dots, droplets, circles, rectangles, squares, triangles, lines, and the like, as well as combinations of patterns.


A length of the top label 300 may be selected to be slightly longer than a circumference of the object on which it is placed, such that the top label trailing edge 304 overlaps the top label leading edge 302, and the top label trailing edge 304 is affixed to the top label leading edge 302. In various embodiments, the length of the top label 300 may be selected to be approximately the same as the circumference of the object on which it is placed, such that both the leading edge 302 and the trailing edge 304 do not overlap and are affixed to the base label front surface 108.



FIG. 5A illustrates the application of the base label 100 to an exemplary container 500 according to various embodiments. The container 500 may be a glass or plastic bottle, or other type of container, such as a metal can or a cardboard receptacle. The container may be round, rectangular, square, or any other shape known in the art. The term “container” is used here for convenience to describe exemplary embodiments. It is understood that the container may be any object, including non-containers. Container 500 may comprise a cap 502 removably secured to a body 504. Various embodiments of the body 504 may have an exterior surface 506 that comprises a upper label panel 508, a lower label panel 510, and a recessed surface 512 interposed between the upper label panel 508 and the lower label panel 510. As discussed below, the base label 100 may be applied to the container 500 at the recessed surface 512 between the upper label panel 508 and the lower label panel 510.


In various embodiments, the top label 300 may be rotatable about the base label 100, as discussed below. In these embodiments, the upper label panel 508 and lower label panel 510 may function to restrict upward and downward movement of the top label 300 in relation to the container 500, such that the top label 300 generally remains in a position covering at least a portion of the base label 100.



FIG. 5B illustrates the container 500 with the base label 100 affixed to the container 500. Initially, as illustrated in FIG. 5A, base label leading edge 102 is placed in contact with the recessed surface 512 of the container 500 and affixed to the container 500 by the leading edge adhesive strip 202. With relative motion between the container 500 and the base label 100, the base label 100 may be wrapped around the container 500 with the base label trailing edge 104 now overlapping the base label leading edge 102, such that the leading edge adhesive strip 202 holds the base label leading edge 102 to the container 500 while the trailing edge adhesive strip 204 holds the base label trailing edge 104 to the overlapped base label leading edge 102.


In various embodiments, as illustrated in FIG. 6, the length of the base label 100 may be substantially the same as a circumference of the recessed surface 512 of the container 500, which may allow the base label leading edge 102 and base label trailing edge 104 to abut rather than overlap. However, it is also possible that the length of the base label 100 may be shorter than the circumference of the recessed surface 512, resulting in a gap 702 between the base label leading edge 102 and the base label trailing edge 104 when the base label 100 is affixed to the recessed surface, as illustrated in FIG. 7. In both of these instances, the base label trailing edge adhesive strip 204 may adhere to the recessed surface 512 of the container 500, rather than the base label leading edge 102.


In various embodiments, the base label adhesive strips 202, 204 may comprise a permanent adhesive. In general, a permanent adhesive is one that does not readily release from a surface to which it adheres after the adhesive dries or cures. Using the base label 100 as an example, the permanent adhesive 202, 204 will tend not to release from the recessed surface 512, nor will it tend to release the base label leading edge 102 or trailing edge 104 once dried or cured. In order to remove the base label from the recessed surface 512, the base label 100 may have to be torn from the adhesive, or the adhesive strips 202, 204 may have to be fractured, which may leave some of the adhesive on the recessed surface 512 and some of the adhesive on the base label leading edge 102 or trailing edge 104. Once the surfaces affixed with the permanent adhesive are separated, they may not be reattached.


In FIG. 8, the base label 100 is already affixed to the recessed surface 512 of the container 500, and the application of the top label 300 over the base label 100 is illustrated according to various embodiments. The top label leading edge 302 may be placed in contact with any portion of the base label front surface 108 and affixed to the base label front surface 108 by the top label leading edge adhesive strip 404. With relative motion between the container 500 and the top label 300, the top label 300 may be wrapped around the container 500 with the top label trailing edge 304 now overlapping the top label leading edge 302 such that the top label leading edge adhesive strip 404 holds the top label leading edge 302 to the base label 100 while the top label trailing edge adhesive strip 406 holds the top label trailing edge 304 to the overlapped top label leading edge 302.



FIG. 9 illustrates the operation of the base label 100 and the top label 300 according to various embodiments. Beginning with the container 500 with the base label 100 and the top label 300 in place as shown, for example, in FIG. 6, the top label trailing edge 304 may be detached from the top label leading edge 302 and at least partially peeled back as shown in FIG. 9. The combination of the base label 100 and the top label 300 in this configuration increases the amount of surface area available for viewing by a consumer or user of the container 500. Prior to detaching the top label trailing edge 304, the consumer may view the top label front surface 306. Upon detaching the top label trailing edge 304, the consumer may now view the top label back surface 402 and the base label front surface 108, in addition to the top label front surface 306.


One of at least three types of adhesive may be used for the top label leading edge adhesive 404. A first type of adhesive is the permanent adhesive as described above for the base label 100. When a permanent adhesive is used for the top label leading edge adhesive 404, the top label leading edge 302 generally cannot be detached without inflicting damage to one or both of the top label 300 or the base label 100. This may be desirable for various embodiments where the top label 300 is not intended to be removed from the container 500.


A second type of adhesive that may be used for the top label leading edge adhesive 404 is a releasable adhesive. A releasable adhesive is one that will release from a surface to which it is attached once a sufficient mechanical force is applied. A releasable adhesive may be used, for example, when the top label back surface 402 comprises a coupon for a subsequent purchase of a product. The releasable adhesive may allow the consumer to easily remove the top label 300 for later use. In various embodiments, the releasable adhesive may be a breakaway adhesive. A breakaway adhesive may have limited ability to withstand shear stresses. Shear stresses may cause the adhesive bond created between the label (e.g., top label 300) and the surface to which it is affixed (e.g., the base label 100 or container 500) to fail along the adhesive. In general, a releasable or breakaway adhesive may not re-attach to a surface once removed.


A third type of adhesive that may be used for the top label leading edge adhesive 404 is a resealable adhesive. A resealable adhesive may release from a surface to which it is attached once a sufficient mechanical force is applied, similar to the releasable adhesive described above. However, the resealable adhesive may be re-attached to a surface by applying pressure. A resealable adhesive may be desirable when the top label back surface 402 or the base label front surface 108 comprise information that may be needed only on occasion. Thus, the consumer or user may detach the top label 300 when the information is needed, then re-attach the top label 300.


In various embodiments, the top label trailing edge adhesive 406 may be a releasable adhesive or a resealable adhesive, depending on the intended use of the top label 300. As described above, if the surfaces 108, 402 comprise information that is intended to stay with the container, the top label trailing edge adhesive 406 may be a resealable adhesive. In contrast, if the top label 300 is intended to be removed from the container 500, a releasable adhesive may be desirable.



FIG. 10 illustrates various embodiments of the top label 300 comprising a window 1002. The window 1002 may comprise a void in the top label 300 such that a portion of the base label 100 may be visible through the window. In various embodiments, the window 1002 may have a transparent covering (not shown). In various other embodiments, the window may comprise a transparent section of the top label 300 itself rather than a void. FIG. 10 illustrates the top label 300 partially wrapped about a container 1000, and base label 100 already in place on the container 1000. As shown, the top label leading edge adhesive 404 maintains the top label 300 coupled to the base label 100. The top label 300 may then be moved from the position illustrated in FIG. 10 to the position illustrated in FIG. 11 to secure the top label 300 about the container 1000. Top label trailing edge adhesive 406 may couple to the top label leading edge 302 if the top label leading edge 302 and trailing edge 304 overlap; otherwise, the top label trailing edge adhesive 406 may be coupled to the base label front surface 108.


Once the top label 300 is in position on the container 1000 as illustrated in FIG. 11, at least a portion of the base label front surface indicia 106 may be visible through the window 1002. This may allow viewing of a first portion of the base label 100 without removing the top label 300. In various embodiments, the top label leading edge adhesive 404 may be a breakaway adhesive. Rotation of the top label 300 relative to the base label 100 may exert shear stresses on the breakaway adhesive, causing the adhesive bond affixing the top label leading edge 302 to the base label 100 to fail. The top label 300 may then be freely rotatable about the base label 100, and a second portion of the base label 100 may be visible when the top label 300 is rotated to a second position. The window 1002 may be rectangular as illustrated in FIGS. 10 and 11, or any other shape as needed for a particular application. For example, the window 1002 may be a slit that reveals an alphanumeric string on the base label 100. In various embodiments, the top label 300 may comprise more than one window 1002. Various embodiments in which the top label trailing edge adhesive 406 is a resealable or releasable adhesive may allow the top label 300 to be peeled back to reveal the top label back surface 402 and essentially the entire base label front surface 108 or to be removed from the container 1000, in addition to being rotatable.


One skilled in the art will readily recognize that labels may be applied to containers using a variety of methods and that there may be a variety of single-label and multi-label systems other than those described above. Any such application methods or label systems may be used with the present disclosure. The above descriptions are exemplary and not to be construed as limiting in any way. Examples of other application methods and label systems may be disclosed in U.S. Pat. Nos. 5,884,421, 6,086,697, 6,237,269, 6,402,872, 6,631,578, 6,649,007, 7,087,298, and 7,172,668.



FIG. 12A illustrates various embodiments of a top label 300 and FIG. 12B illustrates various embodiments of a base label 100 comprising a patient compliance aid that may be used, for example, on a medication container. The base label indicia 106 may comprise a plurality of indicia corresponding to days of the week indicia 1205. As illustrated in FIG. 12B, the day of week indicia 1205 range from Day 1 to Day 20.


Various embodiments of the present invention may comprise a patient compliance aid that may be used, for example, on a medication container 1501. The patient compliance aid may comprise the base label 100 and the top label 300. The base label 100 may contain indicia 106 selected to correspond to a prescribed number of days and frequency per day the medication should be consumed. FIG. 12B illustrates exemplary day of week indicia 1205 indicating “Day 1,” or the first day the medication should be consumed, through “Day 20,” or the last day the medication should be consumed. Alternatively, the day of week indicia 1205 may comprise Monday, Tuesday, Wednesday, etc., repeating for as many days as necessary to consume the medication. Various embodiments of the day of week indicia 1205 may also comprise days of the month, such as March 1, March 2, March 3, etc. Those skilled in the art will recognize that the day of week indicia 1205 may comprise a variety of indicators, and that the day of week indicia 1205 may be customized for each medication container. For example, the day of week indicia 1205 may correspond to the number of days the medication should be consumed (for example, 20 days as illustrated in FIG. 12B), or the days of the month the medication should be consumed (for example, the day of week indicia 1205 may run from March 1 to March 20 for the same 20-day period).


In various embodiments, the base label indicia 106 may comprise time of day indicia 1210, either in conjunction with the day of week indicia 1205 as illustrated in FIG. 12B, or independently. The time of day indicia 1210 may indicate the time of day the medication should be consumed. The time of day indicia 1210 may comprise a variety of symbols as illustrated in FIG. 12B. For example, a circle may indicate that a dose of the medication should be consumed in the morning; a triangle may indicate that a dose should be consumed at noon; a square may indicate that a dose should be consumed in the evening; and a pentagon may indicate that a dose should be consumed at bedtime. In various embodiments, the symbols may also comprise a letter within the symbol to further indicate the time of day the medicine should be consumed. For example, the letter “M” may be placed within the circle to indicate morning, the letter “N” may be placed within the triangle to indicate noon, and so on. Alternatively, all the symbols may be the same (such as circles or ovals) with the appropriate letter within each symbol.


The day of week indicia 1205 and the time of day indicia 1210 may be placed along both a top edge and a bottom edge opposite the top edge of the base label as illustrated in FIG. 12B. In various embodiments, the indicia 1205, 1210 may be placed along one of the top edge or the bottom edge of the base label 100.


One skilled in the art will recognize that any number of symbols may comprise the time of day indicia 1210. For example, FIG. 13 illustrates three symbols that may correspond to consuming the medication in the morning, at noon, and in the evening. Similarly, FIG. 14 illustrates time of day indicia 1210 comprising two symbols, which may indicate that the medication should be consumed in the morning and the evening. Other symbols, letters, numbers, and like may be used as is known in the art.


Returning to FIG. 12B, the base label 100 may have a blank portion 1215 along the leading edge 102 that is essentially void of any indicia 106. As described previously, the trailing edge 104 may overlap the leading edge 102 when the base label 100 is applied to the container. The blank portion 1215 provides a space for attachment of the trailing edge without obscuring any of the indicia 106.


The patient compliance aid may further comprise top label 300 according to various embodiments. Top label 300 may comprise indicia 308 relaying medication-related information, patient-related information, medical-provider related information, and the like. Additionally, the top label may comprise a legend 1220 identifying the time of day indicia 1210, and reminder indicia 1225, which may be used to indicate the next time of day for consumption of the medication as described further below.


The top label 300 may have a height H2 and base label 100 may have a height H1 as illustrated in FIGS. 12A and 12B, respectively. In various embodiments, the height H2 of the top label 300 may be selected to be less than the height H1 of the base label 100, such that either the indicia 1205, 1210 along the top edge of the base label 100 are visible, or the indicia 1205, 1210 along the bottom edge are visible, depending on the placement of the top label 300.



FIGS. 15A-15C illustrate the base label 100 and top label 300 on a medication container 1501 according to various embodiments. In FIG. 15A, the base label 100 is positioned on the medication container 1501, and the base label 100 comprises indicia 1205, 1210 along both the top edge and the bottom edge. FIG. 15B illustrates the top label 300 in place over the base label 100. As described previously, the top label 300 may be applied such that the top label 300 is rotatable around a circumference of the medication container 1501 and slidable up and down along at least a portion of a length of the medication container 1501. In FIG. 15B, the top label 300 has been slid downward in the direction of the arrow revealing the indicia 1205, 1210 along the top edge of the base label 100 and covering the indicia 1205, 1210 along the bottom edge of the base label 100. Similarly, FIG. 15C illustrates the top label 300 slid upwards in the direction of the arrow, thus revealing the indicia 1205, 1210 along the bottom edge of the base label 100 and covering the indicia 1205, 1210 along the top edge of the base label 100.


In FIG. 15B, the top label 300 may be rotated such that the reminder indicia 1225 lines up with the time of day indicia 1210 corresponding to the time the next dose should be consumed. As illustrated in FIG. 15B, the reminder indicia 1225 indicates that the next dose should be consumed in the morning of Day 6. Similarly, when the top label 300 is slid upward, as illustrated in FIG. 15C, the reminder indicia 1225 may be used to indicate the appropriate time of day indicia 1210 along the bottom edge of the base label 100. After each dose is consumed, the patient may rotate the top label 300 so that the reminder indicia 1225 lines up with the next symbol of the time of day indicia 1210.


The day of week indicia 1205 and the time of day indicia 1210 may be markable with a writing instrument, such as a pen or pencil. FIG. 16 illustrates various embodiments in which the time of day indicia 1210 are markable with a writing instrument. The patient may mark the appropriate symbol of the time of day indicia 1210 after taking each dose of the medication. In the example of FIG. 16, the patient has just consumed the evening dose on Day 6 and is marking the square symbol corresponding to the evening dose with a writing instrument 1601. The patient may then rotate the top label 300 until the reminder indicia 1225 lines up with the symbol for the Day 6 bedtime dose.


As illustrated in FIG. 17, the indicia 1205, 1210 may comprise, or alternatively may be coated with, a scratchable substance 1701. In various embodiments, the patient may scratch off the scratchable substance 1701 at the symbol corresponding to the day of week indicia 1205 or time of day indicia 1210 corresponding to a dose consumed by the patient. In various embodiments, the scratchable substance 1701 may not be a coating, but rather may be the base label 100 itself. For example, the base label 100, or a portion of the base label 100 where the indicia 1205, 1210 are located, may comprise the scratchable substance 1701 that darkens when scratched. In the example of FIG. 17, the patient has scratched off the scratchable substance 1701 at the time of day indicia 1210 corresponding to the Day 6 noon dose.


As discussed previously, the top label 300 may comprise a transparent window 1002 to allow writing 106 (other than the day of week indicia 1205 or the time of day indicia 1210) on the base label 100 to be visible when the top label 300 is in place. FIG. 18A illustrates various embodiments of writing 106 on the base label 100 positioned between the indicia 1205, 1210 at the top and bottom edges of the base label 100. When the top label 300 is placed on the medication container 1501 over base label 100, the window 1002 may allow the writing 106 to be visible through the window 1002. As the top label 300 is rotated around the medication container 1501 as indicated by the arrows, the writing 106 positioned along the base label 100 may appear in the window 1002.



FIG. 19A-B illustrate various embodiments of a patient compliance aid for a medication container 1501 comprising a base label 100 and top label 300. The base label may comprise an indicator 1901 that displays a symbol or character that may function to indicate the presence of medication within the medication container 1501, or may function to indicate a quantity of medication removed from the medication container 1501 and administered to a patient. In the examples of FIGS. 19A-B, the top label 300 indicates that the medication container 1501 contains 100 tablets. The indicators 1901 along the top and bottom edges of the base label 100 may correspond to the number of tablets in the medication container 1501. In this example, the indicators 1901 along the top edge of the base label 100 may correspond to number 1 through 50, and the indicators 1901 along the bottom edge may correspond to number 51 through 100. The top label may be slidable upwards and downwards as described previously to reveal the indicators 1901 along the top and bottom edges of the base label 100.


The indicators 1901 may comprise a receiving mechanism associated with the indicators 1901, the receiving mechanism capable of receiving an entry when medication is removed from the medication container 1501. Similar to the indicia 1205, 1210 described previously, the receiving mechanism may comprise a markable surface capable of receiving a mark from a writing instrument such as a pen or pencil, or a scratchable surface. Each time medication is removed from the medication container 1501, one of the symbols or characters comprising the indicator 1901 may be marked or scratched.



FIG. 20 illustrates the 100 tablet medication container of FIG. 19 with the numbers 1-11 of the indicator 1901 marked. This may indicate that 11 tablets have been removed from the medicine container and administered to the patient. Alternatively, marking of the indicator 1901 could have started at 100 and counted backward as each tablet is removed from the medication container 1501. In this example, the next number of the indicator 1901 after the last marked number indicates the number of tablets remaining in the medication container 1501 and available to be administered to the patient.



FIG. 21 illustrates a general flow chart of various embodiments of a method 2100 for patient compliance with a regimen for administration of medication from a medication container. A base label 100 may be applied to a medication container 1501 (step 2105). An indicator 1901 comprising a symbol or character may be displayed on the base label 100 (step 2110). The symbol or character may represent that medication remains in the medication container 1501. A receiving mechanism may be associated with the indicator 1901 (step 2115). The receiving mechanism may comprise a markable or scratchable substance capable of receiving an entry when the medication is removed from the medication container 1501 and administered to the patient. At step 2120, at least a portion of the base label 100 may be covered with a top label 300. In various embodiments, a time indicator may be associated with the indicator 1901 on the base label 100, the time indicator representing a time when the medication should be taken by the patient.


In various embodiments, the day of week indicia 1205, time of day indicia 1210, writing 106, and indicator 1901 may be imprinted, embossed, or molded directly on the medication container in place of all or a portion of the base label 100.


Spatially relative terms such as “under”, “below”, “lower”, “over”, “upper”, and the like, are used for ease of description to explain the positioning of one element relative to a second element. These terms are intended to encompass different orientations of the device in addition to different orientations than those depicted in the figures. Further, terms such as “first”, “second”, and the like, are also used to describe various elements, regions, sections, etc. and are also not intended to be limiting. Like terms refer to like elements throughout the description.


As used herein, the terms “having”, “containing”, “including”, “comprising”, and the like are open ended terms that indicate the presence of stated elements or features, but do not preclude additional elements or features. The articles “a”, “an” and “the” are intended to include the plural as well as the singular, unless the context clearly indicates otherwise.


The present invention may be carried out in other specific ways than those herein set forth without departing from the scope and essential characteristics of the invention. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive, and all changes coming within the meaning and equivalency range of the appended claims are intended to be embraced therein.

Claims
  • 1. A patient compliance aid for a medication container, the patient compliance aid comprising: a base label adhered to the medication container;an indicator on the base label, the indicator displaying a symbol or a character;a receiving mechanism associated with the indicator, the receiving mechanism receiving an entry when medication is removed from the medication container; anda top label covering at least a portion of the base label, the top label having a dual ply construction with a vertical height less than a corresponding vertical height of the base label, the top label configured for rotating around a circumference of the base label and the top label configured for sliding in a vertical dimension over the base label, with the sliding without the rotating resulting in exposure of a previously covered segment of the portion of the base label.
  • 2. The patient compliance aid of claim 1, the patient compliance aid further comprising: a time indicator associated with the indicator on the base label, the time indicator representing a time.
  • 3. The patient compliance aid of claim 2, wherein the time is a time for medication to be removed from the container.
  • 4. The patient compliance aid of claim 2, wherein the time is a time for medication to be administered to a patient.
  • 5. The patient compliance aid of claim 1, wherein the indicator indicates a presence of the medication within the container.
  • 6. The patient compliance aid of claim 1, wherein the indicator indicates a quantity of the medication within the container.
  • 7. The patient compliance aid of claim 1, wherein the indicator indicates a quantity of medication removed from the container.
  • 8. The patient compliance aid of claim 1, wherein the indicator indicates a quantity of the medication within the container to be administered to a patient.
  • 9. The patient compliance aid of claim 1, wherein the indicator indicates a quantity of medication removed from the container and administered to a patient.
  • 10. The patient compliance aid of claim 1, wherein the receiving mechanism also receives an entry when the medication is administered to a patient.
  • 11. A method for patient compliance with a regimen for administration of medication from a medication container, the method comprising: adhering a base label to the medication container;displaying an indicator on the base label, the indicator including a symbol or a character representing that medication remains in the medication container;associating a receiving mechanism with the indicator, the receiving mechanism receiving an entry when the medication is removed from the medication container and administered to the patient; andcovering at least a portion of the base label with a top label, the top label having a dual ply construction with a vertical height less than a corresponding vertical height of the base label, the top label configured for rotating around a circumference of the base label and the top label configured for sliding in a vertical dimension over the base label, with the sliding without the rotating resulting in exposure of a previously covered segment of the portion of the base label.
  • 12. The method of claim 11, the method further comprising: associating a time indicator with the indicator on the base label, the time indicator representing a time when the medication should be taken by the patient.
  • 13. A compliance aid for a medication container, the compliance aid comprising: a base label adhered to the medication container;a day of week indicia on the base label;a time of day indicia associated with the day of week indicia on the base label; anda top label covering at least a portion of the base label, the top label having a dual ply construction with a vertical height less than a corresponding vertical height of the base label, the top label configured for rotating around a circumference of the base label and the top label configured for sliding in a vertical dimension over the base label, with the sliding without the rotating resulting in exposure of a previously covered segment of the portion of the base label.
  • 14. The compliance aid for the medication container of claim 13, wherein the day of week indicia is markable with a pen or pencil.
  • 15. The compliance aid for the medication container of claim 13, wherein the day of week indicia further comprises a scratchable substance.
  • 16. The compliance aid for the medication container of claim 13, wherein the time of day indicia is markable with a pen or pencil.
  • 17. The compliance aid for the medication container of claim 13, wherein the time of day indicia further comprises a scratchable substance.
  • 18. The compliance aid for the medication container of claim 13, wherein the time of day indicia has a shape corresponding to a specific time of day.
  • 19. The compliance aid for the medication container of claim 13, the top label further comprising: a reminder indicia printed on the top label.
  • 20. The compliance aid for the medication container of claim 19, wherein the reminder indicia rotates to correspond to the day of week indicia.
  • 21. The compliance aid for the medication container of claim 19, wherein the reminder indicia rotates to correspond to the time of day indicia.
  • 22. The compliance aid for the medication container of claim 13, the top label further comprising: a transparent window within a portion of the top label.
  • 23. The compliance aid for the medication container of claim 13, wherein the top label slides over the base label.
  • 24. The compliance aid for the medication container of claim 13, wherein the top label rotates over the base label.
  • 25. The compliance aid for the medication container of claim 13, wherein the top label further comprises: a legend identifying the time of day indicia.
  • 26. The compliance aid for the medication container of claim 13, wherein the top label further comprises: any of medication-related information, patient-related information or medical-provider related information.
  • 27. The compliance aid for the medication container of claim 13, wherein the medication container is a bottle.
  • 28. The compliance aid for the medication container of claim 13, wherein the top label slides over the day of week indicia.
  • 29. The compliance aid for the medication container of claim 13, wherein the top label slides over the time of day indicia.
  • 30. The compliance aid for the medication container of claim 13, wherein the base label further comprises: a second day of week indicia on the base label, the second day of week indicia located on an end opposite the day of week indicia.
  • 31. The compliance aid for the medication container of claim 13, wherein the base label further comprises: a second time of day indicia on the base label, the second time of day indicia located on an end opposite the time of day indicia.
  • 32. The compliance aid for the medication container of claim 31, wherein the top label covers one indicia and not the second indicia.
CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims priority to provisional U.S. patent application Ser. No. 61/511,817, filed on Jul. 26, 2011, titled “Reminder Packaging for Improving Adherence for Self-Administered Medications,” which is hereby incorporated by reference in its entirety.

US Referenced Citations (304)
Number Name Date Kind
332208 Noel Dec 1885 A
736035 Stevenson Aug 1903 A
1054826 Cole Mar 1913 A
1064576 Washburn Jun 1913 A
1145367 Herter Jul 1915 A
1312611 Chess Aug 1919 A
1317660 Carlson Sep 1919 A
1334031 Hahn Mar 1920 A
1387625 Stein Aug 1921 A
1486313 Van Antwerp Mar 1924 A
2013616 Rettenmeyer Sep 1935 A
2069609 Hanson Feb 1937 A
2129364 Simons et al. Sep 1938 A
2441607 Walls May 1948 A
2468000 Taylor Apr 1949 A
2487274 Schaffer Nov 1949 A
2504076 Lindblom Apr 1950 A
2706464 North Apr 1955 A
2738564 Guianne Mar 1956 A
2739564 North Mar 1956 A
2844893 Keller Jul 1958 A
2860431 Barnum Nov 1958 A
2931657 Lewis Apr 1960 A
2935814 Freeze May 1960 A
2971283 Parker Feb 1961 A
3233770 Waters Feb 1966 A
3278182 Lescher Oct 1966 A
3374911 White Mar 1968 A
D210767 Anglada Apr 1968 S
3375954 Honkanen et al. Apr 1968 A
3468467 Amberg Sep 1969 A
3488880 Taylor Jan 1970 A
3523623 Dorn Aug 1970 A
3542229 Beyerlein et al. Nov 1970 A
3604584 Shank Sep 1971 A
3633781 Zapata Jan 1972 A
3733002 Fujio May 1973 A
3750317 Morgan Aug 1973 A
3766882 Babbitt, III Oct 1973 A
3779829 Wolff Dec 1973 A
3865671 Kronsder Feb 1975 A
3874977 Pyles Apr 1975 A
3960713 Carey Jun 1976 A
4044889 Orentreich et al. Aug 1977 A
4057251 Jones et al. Nov 1977 A
4072553 Braker et al. Feb 1978 A
4203240 Goodwin May 1980 A
4312523 Haines Jan 1982 A
4318683 Fishbaugh et al. Mar 1982 A
4381615 Lonsmin May 1983 A
4405045 Villa-Real Sep 1983 A
4473429 Crankshaw Sep 1984 A
4505497 Katzman Mar 1985 A
4518450 Warmann May 1985 A
4533586 Roule et al. Aug 1985 A
4567681 Fumei Feb 1986 A
4589943 Kimball et al. May 1986 A
4658974 Fujita et al. Apr 1987 A
4680080 Instance Jul 1987 A
4700976 Loose Oct 1987 A
4724973 Shah Feb 1988 A
4727667 Ingle Mar 1988 A
4732411 Siegel Mar 1988 A
4844760 Dickey Jul 1989 A
4877119 Hosking Oct 1989 A
4918604 Baum Apr 1990 A
4920912 Kirkling May 1990 A
4955153 Albrecht et al. Sep 1990 A
D311423 DeSantis Oct 1990 S
5017261 Zodrow et al. May 1991 A
5048870 Mangini et al. Sep 1991 A
5062917 Zodrow Nov 1991 A
5076613 Kovacs Dec 1991 A
5078826 Rogall Jan 1992 A
5116452 Eder May 1992 A
5154448 Griffin et al. Oct 1992 A
5207011 Coulthard May 1993 A
5209367 Van Musscher et al. May 1993 A
5215622 Schmelzer Jun 1993 A
5263743 Jones Nov 1993 A
5264265 Kaufmann Nov 1993 A
5284363 Gartner et al. Feb 1994 A
5321933 Seifert et al. Jun 1994 A
5324559 Brombacher Jun 1994 A
5342093 Weernink Aug 1994 A
5363576 Piana et al. Nov 1994 A
5370754 Soloman Dec 1994 A
5403635 Hoffman Apr 1995 A
5403636 Crum Apr 1995 A
5405482 Morrissette et al. Apr 1995 A
5462488 McKillip Oct 1995 A
5484167 Donaldson et al. Jan 1996 A
D368234 Dickinson et al. Mar 1996 S
5525383 Witkowski Jun 1996 A
5605230 Marino, Jr. et al. Feb 1997 A
5605730 Treleaven Feb 1997 A
5639529 Gozdecki et al. Jun 1997 A
D383038 Willbrandt Sep 1997 S
D386947 Lapierre et al. Dec 1997 S
5712021 Hernandez Jan 1998 A
5727766 Mayo Mar 1998 A
5727819 Grosskopf et al. Mar 1998 A
5738382 Grosskopf et al. Apr 1998 A
5741381 Dolence et al. Apr 1998 A
5758096 Barsky et al. May 1998 A
5799525 Johnson et al. Sep 1998 A
5800893 Harden Sep 1998 A
5809674 Key Sep 1998 A
5829789 Treleaven et al. Nov 1998 A
5830550 Treleaven et al. Nov 1998 A
5842633 Nurse Dec 1998 A
5863628 Barry Jan 1999 A
5883370 Walker et al. Mar 1999 A
5884421 Key Mar 1999 A
5953170 Glancy Sep 1999 A
5975582 Treleaven Nov 1999 A
6027780 Treleaven et al. Feb 2000 A
6035568 Grosskopf et al. Mar 2000 A
6047488 Tuszkiewicz Apr 2000 A
6048423 Barrash et al. Apr 2000 A
6057019 Barry May 2000 A
D428307 Yeandel Jul 2000 S
6086697 Key Jul 2000 A
6120637 Barry Sep 2000 A
6129802 Key Oct 2000 A
6129959 Mercer et al. Oct 2000 A
6158612 Alpert Dec 2000 A
D436499 Pritchard et al. Jan 2001 S
6212803 Key Apr 2001 B1
6213520 Treleaven et al. Apr 2001 B1
6237269 Key May 2001 B1
6253438 Jespersen Jul 2001 B1
6254138 Rawlings et al. Jul 2001 B1
6258200 Kassab Jul 2001 B1
6267672 Vance Jul 2001 B1
D446687 Furman et al. Aug 2001 S
6270121 Dolan et al. Aug 2001 B1
6274236 Shacklett et al. Aug 2001 B1
6276533 Kaplan Aug 2001 B1
6328832 Otruba et al. Dec 2001 B1
6329034 Pendry et al. Dec 2001 B1
6360462 Mengel Mar 2002 B1
6385878 Key May 2002 B1
6398263 Treleaven et al. Jun 2002 B2
6402872 Key Jun 2002 B1
6413345 Treleaven Jul 2002 B1
D461369 Sims et al. Aug 2002 S
6428639 Oldenburg et al. Aug 2002 B1
6431241 Gonzalo Aug 2002 B1
6454094 Salani Sep 2002 B1
6550171 De Werra et al. Apr 2003 B1
6550512 Yang Apr 2003 B2
6561246 Yang May 2003 B2
6575216 Yang Jun 2003 B2
6581773 Kaplan Jun 2003 B2
6616189 Raming Sep 2003 B2
6622878 Frey Sep 2003 B1
6631578 Key Oct 2003 B2
6649007 Key Nov 2003 B1
6669804 Pendry et al. Dec 2003 B2
6722568 Blanford et al. Apr 2004 B2
6737137 Franko, Sr. et al. May 2004 B2
6752431 Matthews et al. Jun 2004 B1
6755442 Franko, Sr. et al. Jun 2004 B2
6779480 Zamjahn Aug 2004 B2
6786515 Franko, Sr. Sep 2004 B2
6793075 Jeter Sep 2004 B1
6793755 Schaupp et al. Sep 2004 B2
6811640 Franko, Sr. Nov 2004 B2
6904867 Zamjahn Jun 2005 B2
D526847 Freeman Aug 2006 S
7087298 Key Aug 2006 B2
D527583 Freeman Sep 2006 S
D533748 Bresler Dec 2006 S
7172220 Franko, Sr. Feb 2007 B2
7172668 Key Feb 2007 B2
7179514 Olsen et al. Feb 2007 B2
7325510 Giewercer Feb 2008 B2
7601410 Matthews et al. Oct 2009 B2
7621231 McNeely Nov 2009 B2
7628427 Adler et al. Dec 2009 B2
7782479 Handa et al. Aug 2010 B2
7875142 Matthews et al. Jan 2011 B2
7926851 Kaufman Apr 2011 B2
8037628 Kaufman Oct 2011 B2
8043993 Roth et al. Oct 2011 B2
D649396 Wilkens et al. Nov 2011 S
8142596 Valenti, Jr. et al. Mar 2012 B1
8245752 Lingier et al. Aug 2012 B2
8272562 Ziegler Sep 2012 B2
8413884 Lim et al. Apr 2013 B2
8424761 Yanagi Apr 2013 B2
D682088 de Urquijo Carmona May 2013 S
8709198 Key Apr 2014 B2
8727220 Key May 2014 B2
D706624 Key Jun 2014 S
D706625 Key Jun 2014 S
20010004152 Treleaven et al. Jun 2001 A1
20010017181 Otruba et al. Aug 2001 A1
20010025442 Key Oct 2001 A1
20010045741 Shacklett et al. Nov 2001 A1
20010050242 Kaplan Dec 2001 A1
20020015813 Pendry et al. Feb 2002 A1
20020017784 Merry et al. Feb 2002 A1
20020029635 Kremen Mar 2002 A1
20020038685 Key Apr 2002 A1
20020096261 Yang Jul 2002 A1
20020096262 Yang Jul 2002 A1
20020096264 Yang Jul 2002 A1
20020104613 Key Aug 2002 A1
20020130182 Mondie Sep 2002 A1
20020139292 Giewercer Oct 2002 A1
20020185212 Schaupp et al. Dec 2002 A1
20020193225 Raming Dec 2002 A1
20030006606 Franko, Sr. et al. Jan 2003 A1
20030012911 Campbell Jan 2003 A1
20030015105 Dewig et al. Jan 2003 A1
20030030270 Franko, Sr. et al. Feb 2003 A1
20030091819 Franko, Sr. May 2003 A1
20030118768 Sellars Jun 2003 A1
20030137145 Fell et al. Jul 2003 A1
20030175463 Olsen et al. Sep 2003 A1
20030189490 Hogerton et al. Oct 2003 A1
20030201064 Treleaven et al. Oct 2003 A1
20040108237 McClintock Jun 2004 A1
20040123565 Rice et al. Jul 2004 A1
20040166277 Key Aug 2004 A1
20040188998 Henthorn Sep 2004 A1
20040197513 Shacklett et al. Oct 2004 A1
20040207193 Franko, Sr. Oct 2004 A1
20040247863 Scott Dec 2004 A1
20050038558 Keene Feb 2005 A1
20050056203 Giewercer Mar 2005 A1
20050097004 Masse Blume May 2005 A1
20050181165 Franko, Sr. Aug 2005 A1
20050183982 Giewercer Aug 2005 A1
20050190914 Chen et al. Sep 2005 A1
20050209870 Alden Sep 2005 A1
20060029761 Matthews et al. Feb 2006 A1
20060032923 Krupa Feb 2006 A1
20060078701 Glasier Apr 2006 A1
20060145471 Franko, Sr. Jul 2006 A1
20060249950 Kenney et al. Nov 2006 A1
20070029787 Loftin, III et al. Feb 2007 A1
20070034103 Kaufman Feb 2007 A1
20070043530 O'Rourke Feb 2007 A1
20070119542 Williams et al. May 2007 A1
20070209753 Gonzalez et al. Sep 2007 A1
20070209755 Smith Sep 2007 A1
20070213214 Roth et al. Sep 2007 A1
20070221319 Morgan Sep 2007 A1
20070222205 Handa et al. Sep 2007 A1
20070252379 Bethune et al. Nov 2007 A1
20070299693 Jung et al. Dec 2007 A1
20080003391 Franko et al. Jan 2008 A1
20080003410 Shacklett et al. Jan 2008 A1
20080010874 Londino Jan 2008 A1
20080014344 Fort et al. Jan 2008 A1
20080073902 Franko Mar 2008 A1
20080121688 Harrop May 2008 A1
20080176955 Heck et al. Jul 2008 A1
20080208694 Baggott Aug 2008 A1
20080233405 Dronzek, Jr. Sep 2008 A1
20080303264 Kaufman Dec 2008 A1
20080303265 Kaufman Dec 2008 A1
20090236023 Lingier et al. Sep 2009 A1
20090255623 Bagung et al. Oct 2009 A1
20090265188 Lamy et al. Oct 2009 A1
20090294521 de la Huerga Dec 2009 A1
20100043267 Sterling Feb 2010 A1
20100044438 Chen et al. Feb 2010 A1
20100084077 Matthews et al. Apr 2010 A1
20100101681 Kramer et al. Apr 2010 A1
20100228615 Hays Sep 2010 A1
20100240133 Brivanlou et al. Sep 2010 A1
20100295916 Kaufman Nov 2010 A1
20100300599 Fort et al. Dec 2010 A1
20100307947 Marden et al. Dec 2010 A1
20110061802 Raming Mar 2011 A1
20110151115 Lingier Jun 2011 A1
20110169602 Gaffney Jul 2011 A1
20110185606 Londino Aug 2011 A1
20110233095 Seidl Sep 2011 A1
20120006712 Kaplan et al. Jan 2012 A1
20120010299 Kaplan et al. Jan 2012 A1
20120037299 Baeta et al. Feb 2012 A1
20120085828 Ziegler Apr 2012 A1
20120118503 Lorence et al. May 2012 A1
20120125526 Key May 2012 A1
20120175336 Miller et al. Jul 2012 A1
20120268837 Rittenburg et al. Oct 2012 A1
20120279632 Lingier et al. Nov 2012 A1
20120292219 Terwilliger et al. Nov 2012 A1
20130025175 Key Jan 2013 A1
20130025529 Key Jan 2013 A1
20130026747 Key Jan 2013 A1
20130033031 Key Feb 2013 A1
20130036634 Key Feb 2013 A1
20130036641 Key Feb 2013 A1
20130037619 Key Feb 2013 A1
20130043157 Key Feb 2013 A1
20130062239 Key Mar 2013 A1
20130129971 Key et al. May 2013 A1
20140076766 Key Mar 2014 A1
Foreign Referenced Citations (54)
Number Date Country
932891 Apr 2002 AT
1165378 Sep 2004 AT
723118 Nov 2000 AU
932891 Apr 2002 BE
1165378 Sep 2004 BE
932891 Apr 2002 CH
1165378 Sep 2004 CH
69711903.3-08 Apr 2002 DE
1165378 Sep 2004 DE
85214 Mar 1958 DK
932891 Apr 2002 DK
932891 Apr 2002 EP
1165378 Sep 2004 EP
2742501 Jun 2014 EP
932891 Apr 2002 ES
965522 Sep 1950 FR
1114750 Apr 1956 FR
1347102 Nov 1963 FR
2460260 Jan 1981 FR
285514 Oct 1988 FR
2677786 Dec 1992 FR
932891 Apr 2002 FR
1165378 Sep 2004 FR
932891 Apr 2002 GB
1039770 May 2002 HK
1021056 Jul 2002 HK
932891 Apr 2002 IE
1E1165378 Sep 2004 IE
327286 Jul 1935 IT
932891 Apr 2002 IT
204456 Sep 2002 MX
225535 Jan 2005 MX
227727 May 2005 MX
932891 Apr 2002 NL
334683 Nov 1999 NZ
1565 Jul 1888 SE
932891 Apr 2002 SE
WO9819289 May 1998 WO
WO0048161 Aug 2000 WO
WO03017174 Feb 2003 WO
WO2007020628 Feb 2007 WO
WO2012071355 May 2012 WO
WO2013015838 Jan 2013 WO
WO2013015839 Jan 2013 WO
WO2013016364 Jan 2013 WO
WO2013016461 Jan 2013 WO
WO2013019907 Feb 2013 WO
WO2013022495 Feb 2013 WO
WO2013022508 Feb 2013 WO
WO2013023221 Feb 2013 WO
WO2013025947 Feb 2013 WO
WO2013039578 Mar 2013 WO
WO2013043618 Mar 2013 WO
WO2014047077 Mar 2014 WO
Non-Patent Literature Citations (19)
Entry
International Search Report and Written Opinion mailed May 25, 2012 in Patent Cooperation Treaty Application No. PCT/US12/22609, filed Jan. 25, 2012.
International Search Report and Written Opinion mailed May 23, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/022610, filed Jan. 25, 2012.
International Search Report and Written Opinion mailed Oct. 9, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/048021, filed Jul. 24, 2012.
International Search Report and Written Opinion mailed Oct. 23, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/050643, filed Aug. 13, 2012.
International Search Report and Written Opinion mailed Nov. 30, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/055948, filed Sep. 18, 2012.
International Search Report and Written Opinion mailed Jul. 26, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/037395, filed May 10, 2012.
International Search Report and Written Opinion mailed Oct. 16, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/048201, filed Jul. 25, 2012.
International Search Report and Written Opinion mailed Jul. 9, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/031670, filed Mar. 30, 2012.
International Search Report and Written Opinion mailed Oct. 23, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/051228, filed Aug. 16, 2012.
International Search Report and Written Opinion mailed Oct. 16, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/049234, filed Aug. 1, 2012.
International Search Report and Written Opinion mailed Aug. 27, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/040301, filed May 31, 2012.
Newswire, “AccuDial(R) Pharmaceutical, Inc. can put an end to underdosing and overdosing with new line of children's over-the-counter medications”, Jul. 8, 2010 [retrieved Dec. 12, 2013]. Retrieved from Internet: <http://www.newswire.ca/en/story/646945/accudial-r-pharmaceutical-inc-can-put-an-end-to-underdosing-and-overdosing-with-new-line-of-children-s-over-the-counter-medications>.
Accudial Pharmaceutical, Inc. company website, www.accuratedose.com, Oct. 30, 2010 [retrieved Aug. 7, 2012). Retrieved from Internet: <http://web.archive.org/web/20101030115353/http://www.accuratedose.com.ca—english/home>.
Anonymous, “Chest congestion (guaifenesin) liquid”, Internet article, http://dailymed.nlm.nih.gov/dailymed/druginfo.cfm?id=25295. (Oct. 26, 2009).
Anonymous, “Pharmaceutical & medical packaging news”, The packaging magazine for the healthcare industry, 16: 12:76-78, Internet article, http://www.accuratedose.com/corporate/assets/pdf/PMP—MagReprinIDec08.pdf, (Dec. 12, 2008).
A. Abramson, “Start-up has twist on safe doses for kids”, Internet article, http://www.accuratedose.com/corporate/assets/pdf/50840—ACC—PBP—Article. pdf, (Jul. 27,2009).
Anonymous, “Chest congestion guaifenesin oral solution expectorant”, Internet article, http://accuratedose.com/us—english/producUnformation/chest—congestion.html, (Aug. 24, 2011).
International Search Report and Written Opinion mailed Apr. 2, 2012 in Patent Cooperation Treaty Application No. PCT/US2011/061739, filed Nov. 21, 2011.
International Search Report and Written Opinion mailed Feb. 28, 2014 in Patent Cooperation Treaty Application No. PCT/US2013/060220, filed Sep. 17, 2013.
Related Publications (1)
Number Date Country
20130026056 A1 Jan 2013 US
Provisional Applications (1)
Number Date Country
61511817 Jul 2011 US